Tamoxifen, a selective estrogen receptor modulator (SERM), is used as an estrogen antagonist for all stages of breast cancer. Toremifene, a chlorinated derivative of tamoxifen, in a worldwide phase III trial demonstrated similar efficacy and safety for the treatment of advanced breast cancer (1). Tamoxifen’s clinical use is associated with a two to threefold increased risk of endometrial cancer. No conclusive clinical data regarding the effects of toremifene on endometrium are available today (1, 2). A case of a patient who undertook at first tamoxifen and then toremifene is reported.

Endometrial damage by antiestrogens in a postmenopausal breast cancer patient

BETTOCCHI, Stefano;
2002-01-01

Abstract

Tamoxifen, a selective estrogen receptor modulator (SERM), is used as an estrogen antagonist for all stages of breast cancer. Toremifene, a chlorinated derivative of tamoxifen, in a worldwide phase III trial demonstrated similar efficacy and safety for the treatment of advanced breast cancer (1). Tamoxifen’s clinical use is associated with a two to threefold increased risk of endometrial cancer. No conclusive clinical data regarding the effects of toremifene on endometrium are available today (1, 2). A case of a patient who undertook at first tamoxifen and then toremifene is reported.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11369/409124
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact